Skip to content

A study of the suppressive effect of the test food on the elevation of postprandial blood glucose levels

A study of the suppressive effect of the test food on the elevation of postprandial blood glucose levels: a randomized, placebo-controlled, double-blind, parallel-group comparison study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT1030240440
Enrollment
68
Registered
2024-10-29
Start date
2024-11-08
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy individuals (Intended indications and effects: Suppression of blood glucose elevation)

Interventions

Test food: Ginger extract powder Duration: Eight weeks Administration: Take one capsule per day in the morning. Test food: Dextrin Duration: Eight weeks Administration: Take one capsule per day in th

Sponsors

Takara Tsuyoshi
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Japanese 2. Men or women 3. Healthy individuals 4. Individuals aged >= 20 and <= 64 5. Individuals whose fasting blood glucose level is <= 125 mg/dL and whose blood glucose level after consumption of a carbohydrate load (Trelan-G 75 g) is <= 199 mg/dL at screening (before consumption; Scr) 6. Individuals whose incremental area under the curve (IAUC) of postprandial blood glucose level is relatively large at Scr

Exclusion criteria

Exclusion criteria: 1. Individuals who are undergoing medical treatment or have a medical history of malignant tumor, heart failure, or myocardial infarction 2. Individuals who have a pacemaker or an implantable cardioverter defibrillator (ICD) 3. Individuals who are currently undergoing treatment for any of the following chronic diseases: cardiac arrhythmia, liver disorder, chronic kidney disease, cerebrovascular disorder, rheumatic disease, diabetes mellitus, dyslipidemia, hypertension, or any other chronic diseases 4. Individuals who are taking "Foods for Specified Health Uses" or "Foods with Functional Claims" 5. Individuals who are taking or using medications (including herbal medicines) and supplements 6. Individuals who are allergic to medicines and foods related to the test product 7. Individuals who are pregnant, lactating, or planning to become pregnant during this study 8. Individuals who have been enrolled in other clinical studies within the last 28 days before the agreement to participate in this study or plan to participate in another study during this study 9. Individuals who are judged as ineligible to participate in this study by the physician

Design outcomes

Primary

MeasureTime frame
1. The measured values of the IAUC of blood glucose level at eight weeks after consumption (8w)

Secondary

MeasureTime frame
1. The measured values of the maximum blood concentration (Cmax) of blood glucose level at 8w 2. The measured values of blood glucose level at each measurement point (before and 30, 60, 90, and 120 minutes after consumption of the carbohydrate load) at 8w 3. The measured values of insulin and C-peptide at 8w 4. Blood test (triglyceride, cholesterol, alanine transaminase (ALT), aspartate aminotransferase (AST), and gamma-glutamyltransferase (gamma-GT)), blood pressure, body fat percentage, body weight, body mass index (BMI), and waist circumference at 8w

Contacts

Public ContactNaoko Suzuki

ORTHOMEDICO Inc.

group_gakujutsu@orthomedico.jp+81-3-3818-0610

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026